References
- Bray MS , KrushkalJ , LiLet al. Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation101(25), 2877–82 (2000).
- Chapman AB , SchwartzGL , BoerwinkleE , TurnerST. Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int.61(3), 1047–55 (2002).
- Hiltunen TP , DonnerKM , SarinAPet al. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J. Am. Heart Assoc.4(1), e001521 (2015).
- Hottenga JJ , BoomsmaDI , KupperNet al. Heritability and stability of resting blood pressure. Twin Res. Hum. Genet.8(5), 499–508 (2005).
- Snieder H et al. Heritability of central systolic pressure augmentation: a twin study. Hypertension35(2), 574–579 (2000).
- Turnbull F , NealB , AlgertCet al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165(12), 1410–1419 (2005).
- Gupta P , PatelP , ŠtrauchBet al. Risk factors for nonadherence to antihypertensive treatment. Hypertension69(6), 1113–1120 (2017).
- Lefebvre J , PoirierL , PoirierP , TurgeonJ , LacourciereY. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br. J. Clin. Pharmacol.63(5), 575–582 (2007).
- Zineh I , BeitelsheesAL , GaedigkAet al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin. Pharmacol. Ther.76(6), 536–544 (2004).
- Pletcher MJ , McCullochCE. The challenges of generating evidence to support precision medicine. JAMA Intern. Med.177(4), 561–562 (2017).
- Phelps PK , KelleyEF , WallaDMet al. Relationship between a weighted multi-gene algorithm and blood pressure control in hypertension. J. Clin. Med.8(3), (2019).
- Sanada H , JonesJE , JosePA. Genetics of salt-sensitive hypertension. Curr. Hypertens. Rep.13(1), 55–66 (2011).
- van Wieren-de Wijer DB , Maitland-vander Zee AH , de BoerAet al. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J. Hypertens.27(1), 61–68 (2009).
- Psaty BM , SmithNL , HeckbertSRet al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA287(13), 1680–1689 (2002).
- Johnson JA , ZinehI , PuckettBJ , McGorraySP , YarandiHN , PaulyDF. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther.74(1), 44–52 (2003).
- Magvanjav O , McDonoughCW , GongYet al. Pharmacogenetic associations of beta1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 trial (secondary prevention of small subcortical strokes). Stroke48(5), 1337–1343 (2017).
- Turner ST , SchwartzGL , BoerwinkleE. Personalized medicine for high blood pressure. Hypertension50(1), 1–5 (2007).